Navigation Links
Genetic variation alters response to common anti-clotting drug

Millions of people take the anticoagulant drug warfarin to prevent harmful clotting after a heart attack, stroke, or major surgery. But the proper dose of warfarin can vary greatly and can be hard to predict. Some of this variability may boil down to a recently identified gene involved in blood clotting, according to a new study published in the June 2 issue of The New England Journal of Medicine.

By looking at the genetic makeup of people on warfarin, researchers at the University of Washington in Seattle and Washington University in St. Louis learned that variations in a gene involved in blood clotting may explain why certain people require a lower or higher dose of warfarin to get its full benefits. This line of work ultimately could help doctors determine each patient's warfarin dose more quickly and precisely.

The study, part of the NIH Pharmacogenetics Research Network, was supported by three components of the National Institutes of Health (NIH): the National Institute of General Medical Sciences (NIGMS); the National Heart, Lung, and Blood Institute (NHLBI); and the National Institute of Environmental Health Sciences (NIEHS).

"This research points to the value of pharmacogenetics, the study of how genetic variations can alter people's responses to medicines," said NIH Director Elias A. Zerhouni, M.D. "It shows one important way in which we are beginning to apply knowledge about the human genome for treating disease and improving human health."

Warfarin (trade names include CoumadinTM) is the most commonly prescribed oral anti-clotting drug. Allan E. Rettie, Ph.D., University of Washington professor of medicinal chemistry and senior author of the paper, estimated that 2 million people in the United States take warfarin on any given day.

Despite its wide use, physicians find the drug challenging to prescribe.

"There is a narrow window between too much and too little effect," explained Rettie. "A small change in dos
'"/>

Source:NIH/National Institute of General Medical Sciences


Page: 1 2 3

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Genetically modified natural killer immune cells attack, kill leukemia cells
3. Ants Genetic Engineering Leads To Species Interdependency
4. Genetic Variation Visualization - From EMBL
5. Genetically modified rice in China benefits farmers health, study finds
6. Infants With Rare Genetic Disease Saved by Cord Blood Stem Cells
7. Genetically Modified Natural Killer Immune Cells Attack, Kill Leukemia Cells
8. Genetic defects give the immune system the green light to attack the pancreas
9. Maine Researchers Find Exceptions to Old Rules of Genetic Inheritance
10. Genetic therapy reverses nervous system damage in animal model of inherited human disease
11. Infants with Rare Genetic Disease Saved By Cord Blood Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Genetic variation alters response common anti clotting drug

(Date:8/12/2015)... August 12, 2015 As the ... payment innovation and advanced biometrics technology is accelerating beyond ... consumers rely on using their credit cards, the digital ... future for payment services led by companies in the ... :  Google, Inc. (NASDAQ: GOOG ), Apple Inc. ...
(Date:8/12/2015)... , Aug. 12, 2015  Synaptics Inc. ... human interface solutions, today announced that four of ... Match-in-Sensor solution, have officially been named FIDO Certified™ ... part of the certification, Synaptics, Natural ID™ fingerprint ... Universal Authentication Framework (UAF) standard and are interoperable ...
(Date:8/10/2015)... and TELTOW, Germany , ... Instruments (SMI), a world leader in Eye Tracking ... completion of its OEM Eye Tracking Platform for integration ... Tracking Platform contains reference designs for seamless integration of ... systems, virtual reality HMDs and augmented reality smart glasses. ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... defeat is influenced by his or her stance on ... of the most recent presidential and congressional elections. ... candidates, statements on climate change translated into real votes," ... science at Stanford, who led two new studies ...
... Administration (FDA) has awarded the Georgia Institute of ... Saint Joseph,s Translational Research Institute (SJTRI) a two-year, ... medical devices focused on the special needs of ... Pediatric Device Consortium, which will provide assistance with ...
... October 2011, Singapore A new biotech company has ... (NUS), to provide research tools, targeting the international malaria ... founded by two NUS faculty members: Dr Martin Lear ... Tan from the NUS Department of Microbiology. The company ...
Cached Biology News:Stanford researchers examine impact of 'green politics' on recent national elections 2Stanford researchers examine impact of 'green politics' on recent national elections 3FDA grant launches Atlanta Pediatric Device Consortium 2FDA grant launches Atlanta Pediatric Device Consortium 3FDA grant launches Atlanta Pediatric Device Consortium 4Launch of BioLynx provides a boost for the international malaria research community 2
(Date:8/26/2015)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended June 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... our Oral Amp B program, rapidly advancing towards ... Andrew Rae , President & CEO of iCo ...
(Date:8/26/2015)... 2015  Platform therapeutic company Symic Biomedical, Inc. ... $1.5M Phase II SBIR grant from the National ... therapeutic agent to reduce arteriovenous fistula (AVF) failures, ... renal disease (ESRD) patients undergoing hemodialysis. The two-year ... and Digestive and Kidney Diseases (NIDDK), will allow ...
(Date:8/26/2015)... , August 26, 2015 After litigating ... Europlasma NV relating to P2i United States ... their dispute in the United States ... the part of either party. As a result of the ... of California dismissed the case without ...
(Date:8/25/2015)... 25, 2015   WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the pharmaceutical, biotechnology, and medical ... Hong Kong Exchange Stock Code: 0950), a research-based biopharmaceutical ... with 20 years of operations in China ... signed an agreement whereby WuXi,s Laboratory Testing Division (LTD) ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3P2i Settles United States Litigation 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 3
... Board: KDUS) announced today financial results for the first,quarter ended ... 2008 were $100,000, compared to,$100,000 for the same period in ... compared to net loss of $558,469 for the same period ... a decrease in general,and administrative expenses of $47,207 and the ...
... Pharmaceutical Services, Inc.,(JOM), a service coordinator that provides ... Ortho Biotech, L.P., was notified May 6,2008, that ... PROCRIT(R) (epoetin alfa) and REMICADE(R) (infliximab) was,stolen while ... in,Kentucky to a specialty distributor. This incident has ...
... MedImmune today announced,that researchers will present eight ... Annual Meeting of the American Thoracic Society, ... Canada. Presentations are designed to showcase,MedImmune,s biologics ... innovative solutions that may one,day help patients ...
Cached Biology Technology:Cadus Reports First Quarter 2008 Results 2Cadus Reports First Quarter 2008 Results 3Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product 2Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product 3Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product 4Depth of MedImmune's Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society 2
...
Mouse monoclonal [M2II-12] to MRP2 ( Abpromise for all tested applications). entrezGeneID: 1244 SwissProtID: Q92887...
Mouse monoclonal antibody to ANAPC2 - anaphase promoting complex subunit 2...
... MAX POWER 500V Programmable Power Supply ... which can handle virtually any application ... current blotting. It is unique in ... The MAX POWER Programmable Power Supply ...
Biology Products: